Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women

Menopause

Volumn 14, Issue 1, 2007, Pages 38-44

  Di Carlo, Costantino ^a   Tommaselli, Giovanni A ^a   Gargano, Virginia ^a   Sammartino, Annalidia ^a   Bifulco, Giuseppe ^a   Tauchmanova, Libuse ^a   Colao, Annamaria ^a   Nappi, Carmine ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Ghrelin; Leptin; Menopause; Osteocalcin; Osteoprotegerin; RANKL

Indexed keywords

ESTRADIOL; GHRELIN; LEPTIN; NOMEGESTROL; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITOMETRY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PHALANX; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

ADMINISTRATION, CUTANEOUS; BONE DENSITY; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FINGER PHALANGES; HUMANS; LEPTIN; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDE HORMONES; POSTMENOPAUSE; PROGESTINS; RANK LIGAND;

EID: 33846083838     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000227855.04732.7b     Document Type: Article

References (33)

1. Cardenas Morales BE, Perez Campos E. Bibliographic review. The role of hypoestrogenism in postmenopausal osteoporosis: new perspectives. Ginecol Obstet Mex 2003;71:187-194.
2. Anderson MA, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function. Nature 1997;390:175-179.
3. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545.
4. Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055.
5. Kong Y, Yoshida H, Sarosi J, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
6. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000;97:1566-1571.
7. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;237:610-615.
8. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
9. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
10. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-4370.
11. Saika M, Inoue D, Kido S, Matsumoto T. 17-β Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001;142:2205-2212.
12. Oh KW, Rhee EJ, Lee WY, et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol 2004;61:244-249.
13. Liu JM, Zhao HY, Ning G, et al. Relationship between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int 2004;76:1-6.
14. Han KO, Choi JT, Choi HA, et al. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin Endocrinol 2005;62:349-353.
15. Eghbali-Fatourechi G, Khosla S, Sanyal A. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;118:1221-1230.
16. Rogers A, Saleh G, Hannon RA. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-4475.
17. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997;387:206-209.
18. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
19. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblast and to inhibit differentiation to adipocytes. Endocrinology 1999;140:1630-1638.
20. Fukushima N, Hanada R, Teranishi H, et al. Ghrelin directly regulates bone formation. J Bone Mineral Res 2005;20:790-798.
21. Di Carlo C, Tommaselli GA, Sammartino A, Bifulco G, Nasti A, Nappi C. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 2004;11:466-473.
22. Di Carlo C, Tommaselli GA, Pisano G. Serum leptin levels in postmenopausal women: effects of transdermal hormone replacement therapy. Menopause 2000;7:36-41.
23. Block G, Hartman AM, Dresser CM, et al. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-469.
24. Mele R, Masci G, Ventura V, de Aloysio D, Bicocchi M, Cadossi R. Three year longitudinal study with quantitative ultrasound at the hand phalanx in a female population. Osteoporos Int 1997;7:550-557.
25. Wuster C, Albanese C, De Aloysio D, et al. Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity and discrimination power. J Bone Mineral Res 2000;15:1603-1614.
26. Junk K, Lein M, Hosslin K. Osteoprotegerin and receptor activator of the nuclear factor-κA ligand (RANKL) in the serum of healthy adults. Int J Biol Markers 2002;17:177-181.
27. Gambacciani M, Ciaponi M, Cappagli B, Benussi C, De Simone L, Genazzani AR. Climacteric modifications in body weight and fat tissue distribution. Climacteric 1999;2:37-44.
28. Kellokoski E, Poykko SM, Karjalainen AH, et al. Estrogen replacement therapy increases plasma ghrelin levels. J Clin Endocrinol Metab 2005;90:2954-2963.
29. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-1110.
30. Kaufman J, Einhorn TA. Perspectives. Ultrasound assessment of bone. J Bone Miner Res 1993;8:517-525.
31. Ashman RB, Antich PP, Gonzales J, Anderson JA, Rho JY. A comparison of reflection and transmission ultrasonic techniques for measurement of cancellous bone elasticity. J Biomech 1994;27:1195-1199.
32. Tavakoli MB, Evans JA. The effect of bone structure on ultrasonic attenuation and velocity. Ultrasonics 1992;30:389-395.
33. Gluer CC, Hans D. How to use ultrasound for risk assessment: a need for defining strategies [editorial]. Osteoporos Int 1999;9:193-195.